- A medicaid and commercial insured claims-based study to estimate improved antipsychotic medication adherence among patients with schizophreniaBruce Pyenson
Milliman, Inc, One Pennsylvania Plaza, 38th Floor, New York, NY, 10119, USA
J Behav Health Serv Res 40:222-33. 2013..For many of these patients, results show that the administration of once-monthly verifiable therapy would improve compliance...
- An actuarial analysis shows that offering lung cancer screening as an insurance benefit would save lives at relatively low costBruce S Pyenson
Milliman, New York City, New York, USA
Health Aff (Millwood) 31:770-9. 2012..We also believe that payers and patients should demand screening from high-quality, low-cost providers, thus helping set an example of efficient system innovation...
- MAKING THE CASE FOR Biotechnology Reinsurance (BIO-RE)Bruce Pyenson
is a principal and a consulting actuary at Milliman Inc, in New York He can be reached by e mail at or by phone at 646 473 3201
Biotechnol Healthc 5:31-5. 2008..The author proposes a combined cost-management and care-delivery standard that could lessen that threat...
- Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysisKathryn Fitch
Milliman, Inc, New York, NY, USA
Curr Med Res Opin 27:1425-9. 2011..In this claims based analysis of COPD patients, drug therapy treatment patterns including inhaled corticosteroids and long acting bronchodilator use were evaluated by COPD severity level...